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A Randomized, Controlled Clinical Study to 
Assess the Effect of Anodal and Cathodal 
Electrical Stimulation on Periwound Skin Blood 
Flow and Pressure Ulcer Size Reduction in 
Persons with Neurological Injuries 
Anna Polak, PT, PhD; Prof Cezary Kucio, MD, PhD; Prof Luther C. Kloth, MS, PT, FAPTA, 
FACCWS; Malgorzata Paczula, MD; Ewa Hordynska, MD; Tomasz Ickowicz, PT; Prof Ed-
ward Blaszczak, MSc, PhD; Ewa Kucio, MSP, PhD; Krystian Oleszczyk, MD, PhD; 
Prof Krzysztof Ficek, MD, PhD; and Prof Andrzej Franek, MSc, PhD 
Abstract
The use of electrical stimulation (ES) should be considered for treating nonhealing pressure ulcers (PUs), but optimal ES 
wound treatment protocols have yet to be established. A randomized, controlled, double-blind clinical study was con-
ducted to evaluate the effects of cathodal and anodal high-voltage monophasic pulsed current (HVMPC) on periwound 
skin blood flow (PSBF) and size reduction of Stage 2 to Stage 4 PUs of at least 4 weeks’ duration. Persons >18 years of 
age, hospitalized with neurological injuries, at high risk for PU development (Norton scale <14 points; Waterlow scale >15 
points), and with at least 1 Stage 2 to Stage 4 PU were eligible to participate in the study. Persons with necrotic wounds, 
osteomyelitis, electronic or metal implants in the PU area, PUs in need of surgical intervention, acute wound inflamma-
tion, diabetes (HBA1c >7%), diabetic neuropathy, cancer, and/or allergies to standard wound treatments were excluded. 
Patients were randomly assigned to 1 of 3 groups: anodal (AG), cathodal (CG), or placebo (PG) ES. All groups received in-
dividualized PU prevention and standard wound care. In the PG, sham ES was applied; the AG and CG were treated with 
anodal and cathodal HVMPC, respectively (154 μs 100 Hz; 360 µC/second; 1.08 C/day), 50 minutes per day, 5 days per 
week, for a maximum of 8 weeks. PSBF was measured using laser Doppler flowmetry at baseline, week 2, and week 4, 
and wound surface area measurements were obtained and analyzed using a digitizer connected to a personal computer. 
Data analysis utilized the maximum-likelihood chi-squared test, the analysis of variance Kruskal-Wallis test, the Kruskal-
Wallis post-hoc test, and Spearman’s rank order correlation. Nonlinear approximation based on exponential function was 
used to calculate treatment time needed to reduce the wound area by 50%. In all tests, the level of significance was set 
at P ≤.05. Of the 61 participating patients, 20 were in the AG (mean age 53.2 ± 13.82 years), 21 in the CG (mean age 55.67 
± 17.83 years), and 20 in the PG (mean age 52.5 ± 13.18 years). PUs (baseline size range 1.01 cm2 to 59.57 cm2; duration 4 
to 48 weeks) were most frequently located in the sacral region (73.77%) and classified as Stage 3 (62.29%). PSBF at week 
2 was significantly higher in the AG and CG than in the PG (P <.05). Week 4 differences were not statistically significant. 
Wound percentage area reduction calculated at week 8 for the AG (64.10% ± 29.22%) and CG (74.06% ± 23.23%) were 
significantly different from PG ulcers (41.42% ± 27.88%; P = .0391 and P = .0024, respectively). In both ES groups, PSBF 
at week 4 and percent wound surface area reductions between weeks 4 and 8 were positively correlated, but only the AG 
correlation was statistically significant (P = .049). In this study, both ES modalities improved blood flow and wound area 
reduction rate. Studies examining optimal ES treatment times for healing to occur, the effect of comorbidities and base-
line wound variables on ES outcomes, and the nature of the relationship between blood flow and healing are necessary.
Keywords: randomized controlled trial, pressure ulcer, wound healing, electrical stimulation, skin blood flow   
Index: Ostomy Wound Management 2018;64(2):10–29 doi: 10.25270/owm.2018.2.1029
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Clinical practice guidelines1,2 suggest electrical stimula-tion (ES) should be considered for treating recalcitrant 
Stage 2, Stage 3, and Stage 4 pressure ulcers (PUs). The rec-
ommendation is based on A-level strength of evidence from 
controlled trials on PUs in humans.1 
ES influence on blood flow. A common factor that may 
prevent or delay wound healing is compromised perfusion 
of the wound and periwound tissues. In a preclinical, experi-
mental study with 10 healthy volunteers (age 20 to 40 years), 
Petrofsky et al3 investigated whether skin blood flow changes 
induced by ES could be attributed to the electrical current 
effect on nitric oxide (NO) that is known to dilate blood ves-
sels. From the first part of the study,3 the authors concluded 
a 4-minute application of biphasic sine current in the thigh 
area significantly increased skin blood flow compared to its 
pre-ES level (P <.01). In the second part of the study, biphasic 
sine current and iontophoresis with a NO synthetase inhibi-
tor (N-nitro-L-arginine methyl-ester) were applied simulta-
neously to the same part of the body in the same patients. 
A significant reduction in skin blood flow (P <.01) was ob-
served. The authors concluded the increase in skin blood flow 
in the first part of the experiment was caused by the release of 
NO induced by ES. 
A randomized, double-blind, controlled, placebo clinical 
study by Mohajeri-Tehrani et al4 (N = 20) investigated the 
effect of low-intensity direct current on the release of plas-
ma vascular endothelial growth factor (VEGF) and NO in 
patients with diabetic foot ulcerations. After 12 ES sessions, 
a significantly higher level of NO was noted in blood plasma 
in the ES-treated patients compared to patients in the con-
trol (placebo) ES group  (P = .04). A randomized, single-
blind, controlled clinical trial by Asadi et al5 showed ES sig-
nificantly increased wound-fluid levels of hypoxic inducible 
factor-1α and VEGF while decreasing wound surface area 
after 12 sessions of ES with low-intensity direct current ap-
plied at sensory level. In vitro studies by Zhao et al6 and Bai 
et al7 have shown that an electric field (75 to 200 mV/mm) 
induced by a direct current, comparable in amplitude to the 
measurable current of injury at a wound, caused a direct 
release of VEGF by vascular endothelial cells6 and induced 
directional migration, orientation, and elongation of endo-
thelial cells, vascular fibroblasts, and smooth muscle cells.7 It 
also was shown that vascular endothelial cells migrate toward 
the cathode, as opposed to vascular fibroblasts and smooth 
muscle cells that migrate toward the anode.  
The cited preclinical3,6,7 and clinical4,5 studies have dem-
onstrated that direct4-7 and biphasic pulsed3 currents increase 
the release of NO, dilating blood vessels,3,4 stimulating the re-
lease of angiogenetic factors (VEGF4-6 and of hypoxic induc-
ible factor-1α5), and induce reorientation, elongation, and 
migration of endothelial cells as well as vascular fibroblasts 
and smooth muscle cells,7 all of which exert a positive influ-
ence on wound healing. 
Clinical evidence supporting the use of high-voltage 
monophasic pulsed current (HVMPC) for wound treat-
ment. Chronic wounds treated with ES utilize subsensory 
amplitudes of direct and pulsed currents with amperage 
below 1 mA (so-called microcurrents)8,9 as well as sensory 
stimulation below the muscle contraction threshold. Sensory 
ES involves the application of HVMPC10-18 and low-voltage 
monophasic19-21 and biphasic22-24 pulsed currents.  The au-
thors of critical and systematic reviews published in 201425 
and 201726 concluded both high-voltage and low-voltage 
Key Points
• A randomized, controlled clinical study was conducted 
to examine the effect of 2 types of electrical stimulation 
(ES) — cathodal and anodal high-voltage monophasic 
pulsed current — on periwound skin blood flow and size 
reduction of Stage 2 to Stage 4 pressure ulcers (PUs) as 
compared to control (sham) stimulation.
• Sixty-one (61) patients with neurological impairment 
(61 ulcers) received 1 of the 3 interventions 50 minutes 
per day, 5 days per week, for a maximum of 8 weeks.
• The majority of patients had a Stage 3 PU in the sacral 
area for the previous 10 to 13 weeks.
• At week 2, blood flow was significantly higher in both 
ES groups than in the control group, and wound area 
reduction was significantly greater after 8 weeks. 
• Studies to examine optimal ES treatment times for PU 
healing to occur and to increase understanding about the 
relationship between blood flow and healing are needed.
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pulsed currents can produce consistently positive results in 
patients with chronic wounds. 
Several clinical studies compared HVMPC to standard 
wound care (SWC) alone12,15,16 or SWC + sham ES10,11,13,17,18 
to treat PUs,10,11,15-18 venous leg ulcers,12,14 and diabetic foot 
ulcers.13 The main results and methodology of HVMPC 
in PU treatment studies are summarized in Table 1. The 
outcomes of the cited studies10,11,15-18 indicated PU area 
decreased more in the SWC + ES groups than in controls 
treated with HVMPC. 
In reviews of clinical27,28 and epidemiological studies,29 
wound closure was the crucial endpoint in evaluating treat-
ment efficacy. However, clinical studies utilizing ES rarely 
last long enough for closure to be achieved. Only 1 study10 
involved treatment of PUs with HVMPC until full closure. 
In trials that terminated before wounds were closed, the per-
centage wound area reduction from baseline at weeks 4, 6, 
or 12 of treatment was a crucial indicator of treatment ef-
ficacy.11-18 The time during which PU surface area decreases 
from baseline by at least 50% is also important.27-29 
Three (3) clinical studies evaluated changes in wound sur-
face area (WSA) and periwound skin blood flow (PSBF) in 
ulcers that received 2 and 4 weeks of ES with sensory level 
low-voltage, biphasic, pulsed currents.22-24 To address a gap in 
the research literature, this clinical study was designed assess 
the effect of cathodal and anodal high-voltage HVMPC on 
PSBF and WSA reduction in Stage 2 to Stage 4 PUs in adult 
persons with neurological injuries. 
Methods
Study design. This prospective, randomized, blind, con-
trolled, clinical trial was designed to compare PSBF around 
the PU area after 2 and 4 weeks of treatment as well as WSA 
reduction during 8 weeks of treatment between 3 groups of 
patients receiving SWC plus cathodal ES, anodal ES, or sham 
ES, respectively. Parallel treatment of patients in all 3 groups 
and equal numbers of patients in the groups were assumed.
Ethical approval. Ethical approval was granted by the 
Academy Bioethics Commission. 
The trial was prospectively registered with the Australian-
New Zealand Clinical Trials Registry (ANZCTR): ANZCTRN 
12615001281583.
Study enrollment and criteria. Patients screened for the 
study were treated as inpatients at 1 rehabilitation center be-
tween December 1, 2015, and January, 30, 2017. Their eligibility 
to participate was assessed by their physician using the follow-
ing criteria: neurological injuries (spinal cord injury, ischemic 
stroke, and/or blunt trauma to the head); age 18 years or older; 
high risk of PU development (<14 points on the Norton scale 
and >15 points on the Waterlow scale); and Stage 2, Stage 3, or 
Stage 4 PU of at least 0.5 cm2 in size and at least 4 weeks’ dura-
tion located on the pelvic girdle or lower extremities. 
Because it was initially planned that only patients with spi-
nal cord injuries would be enrolled in the trial, this inclusion 
criterion was stated in the ANZCTR registration form. How-
ever, because the number of qualifying patients in the reha-
bilitation center turned out to be insufficient for statistical 
analysis, patients with brain injuries from a cerebral stroke 
or skull trauma also were included. These changes were re-
ported to the ANZCTR. Patients who could not receive ES 
(ie, persons with cancer, electronic implants, metal implants, 
osteomyelitis in the PU area, tunneling, necrotic wounds, and 
PUs requiring surgical intervention), patients with acute in-
flammation in the wound area, and patients with conditions 
impeding wound healing such as diabetes (HbA1c >7%), 
critical wound infection, allergies to standard wound treat-
ment, and/or alcoholism were excluded from the study.
Randomization. Patients were informed in writing by the 
research manager about the aim and course of the study and 
that they could withdraw from the study at any time without 
having to state a reason and without any consequences for 
their further treatment. Patients who consented to partici-
pate in the trial (or whose legal guardians gave consent for 
their inclusion) were randomly assigned to 3 groups.
The study was initially designed to involve 3 groups of 
15 people. Accordingly, a person independent of the trial 
was given 3 sets of 15 slips of paper that were marked with 
letters A, B, and C denoting group assignment: A for the 
SWC + anodal HVMPC group, B for the SWC + cathodal 
HVMPC group, and C for the SWC + sham ES group. The 
person, who was not aware of what the letters meant, insert-
ed the slips into 45 computer-generated, randomly drawn 
envelopes. Once sealed, the envelopes were delivered to the 
main investigator in charge of allocating patients to groups. 
Before the trial commenced, the envelopes were opened 1 at 
a time in the presence of a physiotherapist and the patient 
concerned was directed to the appropriate group. Because 
more persons volunteered to participate in the study than 
originally planned, 3 additional sets of 6 envelopes were 
prepared for each group and the randomization of patients 
proceeded as described. The final sample consisted of 61 
patients. The increased number of participants diminished 
the risk of study bias. 
Blinding. All patients, medical personnel, and research-
ers were blinded as to what type of ES was being applied to 
individual patients (anodal ES, cathodal ES, or sham ES). 
The exceptions were the main investigator and the principal 
physiotherapist who set the equipment to apply active or 
sham ES. The person responsible for statistical analysis also 
was blinded.   
Study variables. Demographic information on the pa-
tients enrolled in the study was obtained from standardized 
participant interviews, physical examinations, the results of 
additional examinations, and the history of concomitant 
diseases. Study variables for assessing wounds, PU risk, and 
patients’ nutritional status were collected with paper-pencil 
instruments and transferred to a data sheet. Other data, such 
as patient case history, blood cell count results, and previous 
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Table 1. Summary of controlled clinical high-voltage monophasic pulsed current (HVMPC) studiesa in patients 
with pressure ulcers (PUs) 
Kloth and 
Feedar10 
(1988)
Griffin et al11 
(1991)
Houghton et 
al15 (2010)
Franek et 
al16 (2012)
Polak et al17 
(2016)
Polak et al18 (2017)
Total number of 
patients 
16 17 34 50 49 63
Number of pa-
tients (ES group)
9 8 16 26 25 CESG=23/C+AESG=20 
Treatment
ES group SWC+ES SWC+ES SWC+ES SWC+ES SWC+ES SWC+CES/SWC+C+AES
Control group SWC+sham ES SWC+sham ES SWC SWC SWC+sham ES SWC+sham ES
ES groups: 
Mean patient age 
(years)
70.1 32.5 50.3 59 79.92 CESG = 79.35/C+AESG 
79.65
Stage of PU 4 2–4 2–4 2–3 2–3 2–4 in both ES groups
Mean baseline 
WSA (cm2)
4.08 2.34 3.48 4.54 10.58 CES = 9.59/C+AES = 7.37 
Mean duration 
of PU
Not reported 4.5 weeks 1.2 years 3.17 months 2.54 months CES 2.41 mo/C+AES 
2.65mo. 
HVMPC methods:
Positioning of 
electrodes:
    Treatment On PU On PU On PU On PU On PU On PU
    Reference 30cm from PU Distally from PU At least 20cm 
from PU
At least 
20cm from 
PU
At least 20cm 
from PU
At least 20cm from PU 
Polarity of treat-
ment electrode
Anode 
(reversed if 
healing prog-
ress was not 
observed) 
Cathode Initially cath-
ode, then re-
versed weekly
Cathode 
1-2 weeks, 
then anode
Cathode CESG – cathode
C+AESG – cathode for first 
week, than anode
Pulse duration/
frequency
100 μs/105 pps Not reported 
/100 pps
50 μs / 100 pps 
for first 20 min; 
10 pps for next 
20 min
100 μs/100 
pps
154 μs/100 pps 154 μs/100 pps
Electric charge 342 μC/s 500 μC/s Not reported  Not 
reported 
250 μC/s 250 μC/s
Duration of ES 45 minutes 60 minutes 40 minutes 50 minutes 50 minutes 50 minutes
Frequency of ES 1 a day/5 a 
week
1 a day/7 a week 8 a day/7 a 
week
1 a day/5 a 
week
1 a day/5 a week 1 a day/5 a week
Total time of ES 
per week
3.75 hours 7 hours 37 hours 4.16 hours 4.16 hours 4.16 hours
Period of treat-
ment
7.3 weeks        20 successive 
days               
12 weeks 6 weeks 6 weeks 6 weeks
Main outcomes:
ES group (ESG) 100% PUs 
closed
WSA i 80% WSA i 70% 
Closed: 
A: 100 % 
Stage 2 PUs; 
B: 33.3% 
Stage 3-4 PUs
WSA i 
88.9%
A: WSA i 88.31 
% closed: 
 B: 45% Stage 
2 PUs 
C: 17.65% Stage 
3 PUs
A: CESG – WSA i 82.34% 
A: C+AESG – WSA i 70.77 
% closed;  
B: 47.8% PUs in CESG 
B: 45% in C+AESG 
(continued)
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treatment results, were obtained from the electronic hospital 
database. The information then was entered to a computer 
database enabling data analysis. 
Wound assessment. Before treatment, patients’ wounds 
were examined by a physician. Patients with PUs covered 
with eschar and with wounds showing signs of acute inflam-
mation were excluded from the study. Patients with a PU cov-
ered with slough or with PUs in the granulation and epitheli-
alization phases were included in the study. Wound depth was 
determined by a physician based on the criteria developed by 
the National Pressure Ulcer Advisory Panel1 (Stage 2 PUs = 
partial-thickness loss of the dermis presenting as a shallow 
open ulcer with a red pink wound bed, no slough; Stage 3 
PUs = full-thickness tissue loss and subcutaneous fat possibly 
visible but not the bone, tendon, or muscles; and Stage 4 PU 
= full-thickness tissue loss, muscle/bone exposed).
PU risk. Patients’ risk of PU development was assessed 
with the Norton scale30 and the Waterlow scale31 with respect 
to factors such as patient gender and age, body composition 
and weight, mobility, concomitant diseases (primarily central 
nervous system injuries, diabetes, anemia), history of smok-
ing, appetite and level of nourishment, and medications used 
(mainly anti-inflammatory drugs, cytostatics, and steroids). 
Nutritional status. In assessing patients’ nutritional sta-
tus, malnutrition was defined as a state resulting from lack of 
intake or uptake of nutrition that leads to altered body com-
position (decreased fat free mass) and body cell mass leading 
to diminished physical and mental function and impaired 
clinical outcome from disease.32 The primary diagnostic cri-
teria of malnutrition included body mass index (BMI) <18.5 
kg/m2 as indicated by the underweight definition created by 
the World Health Organization or combined weight loss and 
reduced BMI.33 
To determine patients’ nutritional status, their blood 
samples also were tested for markers of metabolic disorders, 
anemia, thyroid dysfunction, impaired glycemic control, de-
hydration, protein deficit, hypoalbuminemia, vitamin level, 
indicators of inflammation (C-reactive protein), and ni-
trogen balance.34,35 Diet was reviewed to assess intake of 
healthy and nonhealthy nutrients and fluid losses. Nutri-
tional status was quantified by means of the Nutritional 
Risk Score (2002).36
Anemia. Anemia was diagnosed as hemoglobin level <13.4 
g/dL in men and <12 g/dL in women. In cases where mean 
corpuscular volume (MCV) erythrocyte was <80 fl, blood 
iron concentration was determined. When MCV erythrocyte 
was above 100 fl, blood B
12
 concentration was tested.
Interventions. All patients in the cathodal ES, anodal ES, 
and placebo groups received SWC (prevention measures, 
wound care, and physical treatment) under the supervision 
of the physician and the principle investigator following best 
practices.1,2,37 Each patient was assessed by an interdisciplin-
ary team consisting of a physician, a nurse, a physiotherapist, 
and a dietitian. 
Individualization. The team developed individual wound 
prevention and treatment programs in consideration of pa-
tients’ needs regarding PU prevention and nutritional inter-
vention, the optimization of the wound dressing protocol, 
and incontinence management. To protect the trial partici-
pants from developing more PUs, pressure-redistribution 
surfaces, foam devices, and pillows were used. Patients who 
were immobile were repositioned by a nurse or physiothera-
pist at least every 2 hours, and persons who could move 
were instructed to change position as often as they could. 
Malnourished patients received individual nutritional sup-
port. They were assisted during meals by a nurse or a medi-
cal assistant who made sure the quantity and quality of food 
and liquids they ingested followed the dietitian’s guidelines. 
Nutritional supplementation with proteins, vitamins, and 
minerals was administered when necessary. Patients who did 
Table 1. Summary of controlled clinical high-voltage monophasic pulsed current (HVMPC) studiesa in patients 
with pressure ulcers (PUs) 
Kloth and 
Feedar10 
(1988)
Griffin et al11 
(1991)
Houghton et 
al15 (2010)
Franek et 
al16 (2012)
Polak et al17 
(2016)
Polak et al18 (2017)
Control group 
(CG)
WSA i 28.9% 
over a mean 
period of 7.4 
weeks
WSA i 52%  WSA i 36% 
Closed: 
A: 100% Stage 
2 PUs; 
B: 7.1% Stage 
3-4 PUs
WSA i 44.4 
%
A: WSA i 54.65 
% Closed: B: 
35.29% Stage 
2 PUs C: 6.25% 
Stage 3 PUs
WSA i 40.53% 
Closed: 
B: 0% PUs
Level of signifi-
cance (P)  
Not reported P(ESG:CG)=.05 A: P(ESG:CG) 
=.048 
B: P(ESG:CG) 
=.62 
C: P(ESG:CG) 
=.55
P(ESG:CG) 
=.00003
A: P(ESG:CG) 
=.046 
B: P(ESG:CG) 
=.74 
C: P(ESG:CG) 
=.60
A: P(CESG:CG)=.0006;  A: 
P(C+AESG:CG) =.0124; A: 
P(CESG:C+AESG)=.9932; 
B: P(CESG:CG) = .013;  
B: P(C+AESG:CG) = .045; 
B: P(CESG:C+AESG)=.48 
a double-peaked impulses; amperage at sensory level
ES=electrical stimulation; PU=pressure ulcers; SWC=standard wound care; WSA=wound surface area; ESG=electrical stimulation group; CG=control group; 
CESG=cathodal ES group; C+AESG=cathodal + anodal ES group; mo=months; no=number 
DO
 N
OT
 D
UP
LIC
AT
E
16     OSTOMY WOUND MANAGEMENT®  FEBRUARY 2018 www.o-wm.com
FEATURE
not consume sufficient amounts of food received enteral or 
parental nutrition.1
Wound care protocol. Wounds were regularly assessed by 
the physician throughout the period of the study with a view 
to selecting topical treatments to appropriately address mois-
ture control, bacterial burden, and debridement needs. When 
wound infection was suspected, a swab was taken to identify 
the bacteria and prepare an antibiogram. 
Before ES was applied, necrotic tissue was removed 
from PUs with surgical/sharp, conservative sharp, or en-
zymatic debridement.
A moist wound environment was maintained consistently 
with hydrogel, hydrocolloid, or alginate dressings. Dressing 
type depended on the PU stage, phase of healing, the amount 
of wound secretion, and pain severity. Wounds covered 
with slough and granulating wounds were covered between 
ES procedures with alginate dressings (high or moderate 
exudate levels; surface and deep wounds) and hydrocolloid 
dressings (moderate or low exudate levels; surface wounds). 
Granulating and epithelializing wounds with minimal exu-
date were covered between ES procedures with hydrocolloid 
or hydrogel dressings.
Infected wounds were washed with antiseptics that in-
cluded Octenilin Wound Gel (Schülke, Norderstedt, Ger-
many); Octenisept solution (Schülke); and/or Actolind W 
Solution/Gel (Polvet Healthcare Teodorowski SJ, Laziska, 
Gorne, Poland). PUs also were washed with Kodan Tinktur 
forte solution (Schülke) and Skinsept (Ecolab, Monheim am 
Rhein, Germany). According to the information provided by 
the manufacturers of these antiseptic agents, none of them is 
cytotoxic to healthy cells. 
Patients with elevated leukocyte levels received antibiotics 
selected according to the results of microbiological culture 
and sensitivity tests. All immobile patients received low-mo-
lecular-weight heparin.
Anodal ES group (AG). Patients in the AG were admin-
istered SWC and anodal HVMPC energy. The device used 
to deliver HVMPC was the Intelect Advanced Combo unit, 
Model 2771 (Chattanooga Group, Vista, CA) with 2 inde-
pendent electrical circuits, of which only 1 was active. The 
device generated a twin-peak monophasic pulse (154 µs) 
consisting of 2 77-µs exponential pulses in rapid succession. 
Pulse frequency was set at 100 pps and voltage above 100 V 
for amperage of 0.36 A that did not elicit motor reactions. 
The electrodes delivered a 360 µC per second charge (1.08 
C per day). Patients participated in 5 50-minute, once-a-
day sessions held weekdays (Monday through Friday). All 
patients had a personal set of conductive carbon-rubber 
electrodes. During the procedure, the treatment electrode 
(5.0 cm x 10.0 cm) was placed on the wound and the re-
turn electrode (10.0 cm x 10.0 cm) was attached to healthy 
periwound skin at least 20 cm from the PU. Both electrodes 
were separated from the tissue by aseptic gauze pads satu-
rated with physiological saline. 
Cathodal ES group (CG). HVMPC protocol in the CG 
was almost the same as the AG protocol; the only difference 
was cathodal (not anodal) stimulation was used. The proto-
col of HVMPC in both ES groups was based on methods used 
in earlier clinical trials using anodal10 and cathodal11,14,17,18 ES 
in patients with PUs10,11,17,18 and venous leg ulcers.14
Placebo ES group (PG). This group received SWC and 
sham ES. The arrangement of electrodes during the proce-
dure was the same as in the ES groups. The monitor of the ES 
unit displayed all parameters, but because the electrodes were 
connected to the inactive electrical circuit current energy was 
not delivered to wounds. 
The main physiotherapist connected the electrodes and 
selected the polarity of the treatment electrode. The proce-
dure was performed in an inconspicuous manner so neither 
the patient nor the members of the medical team could see 
whether real or sham ES was applied. In the active ES groups, 
voltage was set above 100 V (the same value was displayed 
on the monitor for patients receiving sham ES), which did 
not cause muscle contractions, only weak tactile sensations. 
Because most patients in the groups had tactile sensory im-
pairments and did not feel the current, patients in the sham 
ES group did not know they were not receiving treatment. 
All treatment sessions had the same duration and frequency 
(50-minute sessions, once a day, 5 times a week) and followed 
the same protocol whether sham or active ES was applied. 
The electrodes were sterilized before and after each ses-
sion in an approved disinfectant solution (Incidin Liquid and 
Sani-Cloth Active, Ecolab). As soon as the procedure ended, 
patients’ wounds were thoroughly washed with a 0.9% so-
dium chloride solution and covered with SWC dressings as 
described earlier.
The trial design assumed wounds would be monitored for 
8 weeks in all groups, representing the average length of stay 
in the facility. Patients hospitalized longer than 8 weeks were 
to be treated and monitored for wound healing as before. In 
patients with more than 1 PU, all wounds were treated, but 
only the deepest PU (the most advanced stage) was included 
in the study analysis.
Measures/data collection. 
PSBF. PSBF was measured using a laser Doppler imager 
(PERIFLUX 5000, Perimed, Järfälla, Sweden) linked to a per-
sonal computer with the PeriSoft software for Windows (ver-
sion 25.5; Galen Ortopedia Sp z o.o., PL, Bierun, Poland) that 
also was used for making computations and storing the re-
sults. A single point, infrared (IR), laser blood flow probe was 
used; it was calibrated before each measurement. To ensure 
the stability of readings, the laser was warmed for 15 minutes 
before measurement commenced. The probe was attached to 
the skin using a small piece of adhesive tape. Over the 4 weeks 
of treatment, 3 blood flow tests were conducted: before the 
first treatment session, at week 2 (after 10 ES procedures), 
and at week 4 (after 20 ES procedures). All measurements 
were conducted in the patient’s room, usually in an ambient 
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temperature of 21˚ C to 22˚ C. Patients could assume a po-
sition that was comfortable for them (supine or sidelying). In 
preparation for the measurement of skin blood flow, the skin 
around the wound first was washed with aseptic fluid. Using 
the patient’s head as the 12 o’clock reference point, the laser 
probe was attached to wound edges at 4 points (superior, in-
ferior, right, and left side of the wound). At each point, blood 
flow was measured for 20 seconds. The temperature under 
the probe was maintained at all times at a constant level of 
33˚ C. The authors of other clinical trials used a similar pro-
tocol to measure skin blood flow.38      
Wound measurements. Wound (cm2) measurements 
were taken and area calculated at baseline and after each week 
of therapy. If a PU closed before week 8 ended, the day it 
closed was recorded. The WSA was determined by tracing the 
wound shape onto acetate sheets and from the sheets onto 
rigid, transparent film for measurement with a planimeter. 
Measurements were processed by a digitizer (Mutoh Kurta 
XGT; ALTEK Information Technology Inc, (Spokane, WA) 
connected to a personal computer with the C-GEO software 
(version 4.0; Nadowski SoftLine, PL, Tychy, Poland) that 
also was used for making computations and storing the re-
sults. Measurement errors caused by irregular wound shapes 
ranged from 2.7% (for PUs of 70 cm2 in size) to 37.9% (PUs 
<1 cm2). The method used to estimate wound size has been 
presented in an earlier study.16
Primary outcome. The primary outcome of the trial was 
PSBF at weeks 2 and 4 of treatment and between-group dif-
ferences in the flow. To compare the study groups, percentage 
changes in PSBF at weeks 2 (PSBF 2-0) and 4 (PSBF 4-0) were 
calculated using equations 1 and 2 described in Table 2. 
Secondary outcomes. The secondary outcome was the 
rate of change in wound area. It was estimated as the nonlin-
ear approximation of the time during which PU area would 
decrease from baseline by 50% (T½). First, the nonlinear 
approximation of the relative wound area in each week of 
treatment (WSA
rel
[t]) was calculated to ensure the compa-
rability of WSA change rates regardless of treatment length 
Table 2. Wound outcome calculations
Indicator Formula Abbreviation/description 
Equation 1 Percentage change in PSBF 
at week 2 from baseline (%)
PSBF2-0 = (PSBF2 – PSBF0) x 
100%/PSBF0  
PSBF2-0 – Percentage change in 
PSBF at week 2 from baseline (%) 
PSBF2 – PSBF at week 2 [perfusion 
units] PSBF0 – PSBF at baseline 
(perfusion units) 
Equation 2 Percentage change in PSBF 
at week 4 from baseline (%)
PSBF4-0 = (PSBF4 – PSBF0) x 
100%/PSBF0 
PSBF4-0 – Percentage change in 
PSBF at week 4 from baseline (%) 
PSBF4 – PSBF at week 4 (perfusion 
units) PSBF0 – PSBF at baseline 
(perfusion units) 
Equation 3 Relative WSA at a given 
week of treatment (cm2)
WSArel(t) = WSA (t)/WSA (t=0) WSArel(t) - relative WSA (cm
2])WSA 
(t) – WSA at given week’s end (cm2) 
WSA (t=0) – baseline WSA (cm2) 
Equation 4 Nonlinear approximation 
exponential function used to 
calculate T½
WSArel(t) = WSA = 2 
-t/T1/2
WSArel(t) - relative WSA area (cm
2) t 
– week of treatment T½   – approxi-
mate time that WSA would need to 
decrease by half. 
Equation 5 Percentage WSA reduction 
at week 8 (%)
PAR 8 = (WSA 0 – WSA 8) x 100%/
WSA 0
PAR 8 - percentage WSA reduction 
at week 8 (%) WSA 0 – initial WSA 
(cm2) WSA 8 – WSA at week 8 (cm2)    
Equation 6 Percentage WSA reduction 
at week 2 (%)
PAR 2 = (WSA 0 – WSA 2) x 100%/
WSA 0
PAR 2 - percentage WSA reduction 
at week 2 (%) WSA 0 – initial WSA 
(cm2) WSA 2 – WSA at week 2 (cm2) 
Equation 7 Percentage WSA reduction 
at week 4 from week 2 (%)
PAR 2-4 = (WSA 2 – WSA 4) x 
100%/WSA 2
PAR 2-4 percentage WSA reduction 
at week 4 from week 2 (%) WSA 2 – 
WSA at week 2 (cm2) WSA 4 – WSA 
at week 4 (cm2) 
Equation 8 Percentage WSA reduction 
at week 8 from week 4 (%)
PAR 4-8 = (WSA 4 – WSA 8) x 
100%/WSA 4
PAR 4-8 percentage WSA reduction 
at week 8 from week 4 (%) WSA 4 – 
WSA at week 4 (cm2) WSA 8 – WSA 
at week 8 (cm2) 
PSBF=periwound skin blood flow; WSA= wound surface area 
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(see equation 3 in Table 2). For the sake of illustration, the 
relative wound area of 20 cm2 at week 0 (baseline) was calcu-
lated as WSA
rel
(0) = WSA (0)/WSA (t=0) = 20 cm2/20 cm2 = 
1. For a wound area of 15 cm2 at week 1, the relative area is 
given by WSA
rel
(1) = WSA (1)/WSA (t=0) = 15 cm2/20 cm2 = 
0.75 cm2. In the next step, the nonlinear approximation was 
performed using the exponential model presented as equa-
tion 4 in Table 2. Percentage wound area reduction at week 2 
and 8 also was calculated (see Table 2). Finally, the number of 
PUs closed during the 8-week study and duration of time to 
closure for ulcers that healed were analyzed, and correlations 
between PSBF and changes in wound area were examined. 
Statistical analysis. All statistical analyses were performed 
by a person blinded to the ES devices using Statistica software 
(version 13.0, StatSoft Polska Sp. z o.o, Krakow, Poland). In 
all tests, the level of significance was P ≤.05.
Group sizes for the trial were determined through a pilot 
of this study during which 3 groups of 4 patients with PUs 
were treated with AG, CG, and PG. At week 2, percentage 
changes in PSBF from baseline were calculated and compared 
between pairs of groups: AG and PG and CG and PG. The 
greatest standard deviation of PSBF2 calculated for the groups 
(92.38%) and the smallest between-group difference for PSBF2 
(75.00%) indicated that statistically significant between-group 
differences (at P <.05) in PSBF2 could be obtained with groups 
of at least 12 participants. Taking advantage of the fact that 
the number of patients willing to participate in the study was 
greater than originally planned, enrollment continued and the 
final sample was enlarged to 61 patients to reduce the risk of 
error if some of them dropped out before the end of treatment. 
Because PSBF values obtained at the end of treatment 
were considerably different from those calculated with the 
pilot study data, the relative values of PSBF were subjected 
to statistical analysis to minimize the risk of baseline interpa-
tient differences biasing the results of the main study. Relative 
values also were used to estimate changes in WSA at week 8 
(PAR8) and the amount of time necessary for WSA to de-
crease by half (WSA
rel
[t]) (nonlinear approximation) and to 
calculate correlations between PSBF and percentage reduc-
tions in wound area between weeks 0 and 2 (PAR 0-2), 2 and 
4 (PAR 2-4), and 4 and 8 (PAR 4-8).
To retain data of all randomly allocated participants, an 
intent-to-treat analysis was performed. Data that were not 
available were approximated using an exponential regression 
function written as WSA = b exp(-at), where WSA is wound 
surface area; b and a are respectively, the regression constant 
and the exponential regression coefficient calculated for each 
patient using WSA (cm2) obtained over the period of treat-
ment; exp is the exponential regression function with a base 
of e ≈ 2.718282 (the Euler’s number); and t is the week of 
treatment. The function allows WSA decreases39 to be de-
scribed and can be calculated with data from at least 3 weeks. 
The exponential correlation coefficient proved negative for 
each patient and higher than 0.9 for the absolute WSA.
Patient characteristics were tested for normal distribution 
using the Shapiro-Wilk W-test, which showed their distribu-
tion was not normal. The Levene test revealed heterogene-
ity of variance. Despite the absence of normal distribution 
and because of low absolute values of skewness and kurtosis 
(<2.5), a mean was used as the central value and standard 
deviation as a measure of dispersion.
The homogeneity of patients’ characteristics between 
groups was assessed using the maximum-likelihood chi-
squared test, the analysis of variance (ANOVA) Kruskal-Wal-
lis test, and the Kruskal-Wallis post-hoc test. 
To compare test and control groups’ mean PSBF2, PSBF4, 
and PAR8, the ANOVA Kruskal-Wallis test and the Kruskal-
Wallis post-hoc test were employed. The nonlinear approxi-
mation was calculated using the exponential function (equa-
tion 4, see Table 2). 
PSBF and PAR were tested for correlation with Spear-
man’s rank order correlation. 
The following correlations were calculated between: 
1) skin blood flow at baseline (PSBF0) and the per-
centage change in wound surface area noted at week 
2 of treatment (PAR 2; equation 6 in Table 2);
2) skin blood flow at week 2 (PSBF2) and a change in 
wound surface area from week 2 to week 4 (PAR 2-4; 
equation 7 in Table 2); and
3) skin blood flow at week 4 (PSBF4) and change in 
wound surface area from week 4 to week 8 (PAR 4-8; 
Equation 8 in Table 2).
Results
Of the 73 persons screened for the trial, 12 failed to meet 
the inclusion criteria. The other 61 persons were randomly 
assigned to groups AG (20), CG (21) and PG (20). Between 4 
and 8 weeks of treatment, 19 individuals (31.15%) dropped 
out from the trial. A statistical analysis was applied to all data 
obtained, including data from patients who dropped out be-
tween weeks 4 and 8. The flow of participants through the 
trial is illustrated in Figure 1.
Baseline patient and wound characteristics.
Sample characteristics. Of the 61 patients enrolled in the 
trial, 27 were women (44.26%) and 34 were men (55.74%), 
age range 22–78 years. The risk of PU development, assessed 
with the Norton and Waterlow scales, was <14 points and 
>15 points, respectively, for all patients; 10 patients (16.39%) 
were obese (BMI >30) and 16 (26.23%) were considerably 
underweight (BMI <18.5); 45 patients (73.77%) were immo-
bile and needed assistance to change positions; 23 (37.70%) 
smoked cigarettes before they became ill; and 35 (57.38%) 
were malnourished and administered nutrition therapy. 
Twenty-seven (27) patients (44.26%) had spinal cord in-
jury, 32 (52.46%) had experienced a cerebral stroke, and 3 
(4.92%) had a head injury. Tetra- or quadriplegia was diag-
nosed in 21 (34.43%) patients, 19 (31.15%) had paraplegia, 
and 20 (32.79%) had hemiparesis. Nineteen (19) patients 
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(31.15%) had type 2 diabetes and 26 (42.62%) had ane-
mia. The 61 PUs treated as part of the protocol ranged in 
size from 1.01 cm2 to 59.57 cm2; 9 were Stage 2 (14.75%), 
38 were Stage 3 (62.29%), and 14 were Stage 4 (22.95%). 
Most PUs were located in the sacral region (45; 73.77%); 7 
(11.45%) were located on the ischial tuberosity or the tro-
chanter and 9 (14.75%) on the lower extremities (lower leg 
and foot). Forty (40; 65.57%) patients had more than 1 PU. 
The duration of the study PUs varied from 4 to 48 weeks. At 
baseline, most PUs (41; 67.21%) had started to granulate, 16 
(26.23%) wounds were covered with slough, and in 4 wounds 
(6.56%) reepithelialization occurred. Between ES treatments, 
hydrogel dressings were applied in 38 (62.3%) patients, hy-
drocolloid dressings in 16 (26.2%) patients, and alginate in 
7 (11.5%) patients. PSBF measured at baseline ranged from 
9.33 to 86.08 perfusion units, and blood flow in healthy skin 
approximately 20 cm to 30 cm from the wound edges was 4.3 
to 34.92 perfusion units.    
According to the baseline demographic and wound char-
acteristics of the patients (see Table 3), the groups were not 
significantly different for any of the characteristics consid-
ered (P >.05).  
Anodal ES group characteristics. The AG included 20 
patients (8 women, 12 men, average age 53.2 ± 13.82 years). 
Mean PU risk on the Norton and Waterlow Scales was 10 
± 2.63 and 31.3 ± 6.96, respectively. Two (2; 10%) patients 
were obese (BMI >30), 6 (30%) were underweight (BMI 
<18.5), 15 (75%) were immobile and needed assistance to 
change position, 8 (40%) smoked cigarettes, and 11 (55%) 
were malnourished and were administered nutrition therapy. 
Nine (9) patients (45%) had spinal cord injury, 10 (50%) had 
experienced a cerebral stroke, and 1 (5%) had a head injury. 
Six (6; 30%) patients had tetra- or quadriplegia, 7 (35%) 
had paraplegia, and 6 (30%) had hemiparesis. Five (5) pa-
tients (25%) had type 2 diabetes and 9 (45%) had anemia. 
The patients had a total of 20 PUs, mean size 17.88 ± 16.68 
cm2: 2 PUs were Stage 2 (10%), 13 Stage 3 (65%), and 5 Stage 
4 (25%). Most PUs were located in the sacral region (15; 
75%), 2 (10%) were located on the ischial tuberosity or the 
trochanter, and 3 (15%) on the lower extremities (lower leg 
and foot). The mean duration of the PUs was 13.9 ± 11.21 
weeks. Twelve (12; 60%) patients had more than 1 PU. At 
baseline, most PUs (13; 65%) started to granulate, 6 (30%) 
were covered with slough, and reepithelialization occurred in 
1 wound (5%). Between ES treatments, hydrogel dressings 
were applied in 13 (65%) patients, hydrocolloid dressings in 
4 (20%), and alginate in 3 (15%). The mean PSBF was 46.42 
± 20.42 perfusion units, and blood flow in healthy skin ap-
proximately 20 cm to 30 cm from the edges of the wound was 
12.53 ± 7.13 perfusion units. 
Figure 1. Flow diagram of the study.
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Table 3. Baseline patient and pressure ulcer characteristics (N=61)
Variable Anode ES group Cathode ES group Placebo ES group 
Sample size (n) 20 21 20
aGender (n): Female/Male 8 (40%)/12 (60%) 11 (52.38%)/10 (47.62%) 8 (40%)/12 (60%)
bAge [years]:  
  Mean (SD) 53.20 (13.82) 55.67 (17.83) 52.50 (13.18)
  Median/Lower - upper quartile 53.5/47-61 55/53-70 53/49-61 
aBody mass index (BMI) (n, %): 
  BMI >30; 2 (10%) 6 (28.57%) 2 (10%)
  BMI <18.5 6 (30%) 5 (23.81%) 5 (25%)
aNorton scale (points) 
  Mean (SD) 10 (2.63) 9.72 (2.31) 10.05 (1.96)
  Median/Lower–upper quartile 10/8-12 10/8-12 10/8.5-12
aWaterlow scale (points) 
  Mean (SD) 31.3 (6.96) 30.5 (6.83) 31.8 (8.13)
  Median / Lower - upper quartile 30/27-37 30.5/25-34 32.5/25-37.5
aEtiology of neurological injury (n, %):
  Spinal cord injury 9 (45%) 8 (38.10%) 10 (50%)
  Cerebral stroke 10 (50%) 13 (61.90%) 9 (45%)
  Head injury 1 (5%) 1 (4.76%) 1 (5%)
aTetra/Quadriplegia (n, %) 6 (30%) 6 (28.57%) 9 (45%)
aParaplegia (n, %) 7 (35%) 7 (33.33%) 5 (25%)
aHemiparesis (n, %) 6 (30%) 8 (38.10%) 6 (30%)
aConcomitant diseases (n, %)
  Diabetes (HbA1c <7%) 5 (25%) 8 (38.10%) 6 (30%)
  Anemia 9 (45%) 11 (52.38%) 6 (30%)
b,cMalnourished (n, %) 11 (55%) 11 (52.38%) 13 (65%)
a,bWSA of PUs (cm2) 
  Mean (SD) 17.88 (16.68) 19.25 (16.47) 25.12 (17.42)
  Median / Lower–upper quartile 10.68 /4.76-22.08 14.31 5.05-26.35 21.66/9.66-42.38 
b,cSkin blood flow (perfusion unit)
In the ulcer area
  Mean (SD) 46.42 (20.42) 37.37 (21.50) 45.61 (15.73)
  Median/Lower–upper quartile 49/37.68-56 30.85/15.66-60.67 44.81/34.22-55.89
In healthy skin 30 cm from PU
  Mean (SD) 12.53 (7.13) 12.07 (7.52) 13.76 (4.54)
  Median/Lower - upper quartile 10.64/8.01-14.41 10.26/6.23-17.15 13.82 / 10.23-16.36
b,cDuration of PUs (weeks):
  Mean (SD) 13.90 (11.21) 11.62 (8.98) 10.85 (8.59)
  Median /Lower–upper quartile 9/8–13 8/8-12 8/6-12
aPU depth/stage (NPUAP staging, n, %) 
  Stage 2 2 (10%) 4 (19.05%) 3 (15%)
  Stage 3 13 (65%) 12 (57.14%) 13 (65%)
  Stage 4 5 (25%) 5 (23.81%) 4 (20%)
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Cathodal ES group characteristics. The CG included 
21 patients (11 women, 10 men, average age 55.67 ± 17.83 
years). The mean PU risk per the Norton and Waterlow Scales 
was 9.72 ± 2.31 and 30.5 ± 6.83, respectively. Six (6) patients 
(28.57%) were obese (BMI >30) and 5 (23.81%) were un-
derweight (BMI <18.5). Eighteen (18) patients (85.71%) 
were immobile and needed assistance to change position, 
6 (28.57%) smoked cigarettes, and 11 (52.38%) were mal-
nourished and were administered nutrition therapy. Eight 
(8) patients (38.10%) had spinal cord injury, 13 (61.90%) 
had experienced a cerebral stroke, and 1 (4.76%) had a head 
injury. Six (6) patients (28.57%) had tetra- or quadriplegia, 
7 (33.33%) had paraplegia, and 8 (38.10%) were diagnosed 
with hemiparesis. Eight (8) patients (38.10%) had type 2 dia-
betes and 11 (52.38%) had anemia.   
The average size of the 21 PUs was 19.25 ± 16.47 cm2; 
4 were Stage 2 (19.05%), 12 were Stage 3 (57.14%), and 5 
were Stage 4 (23.81%). At baseline, most PUs were located 
in the sacral region (16; 76.19%), 2 (9.52%) were on the 
ischial tuberosity or the trochanter and 3 (14.29%) on the 
lower extremities (lower leg and foot). The mean duration 
of the PUs was 11.62 ± 8.98 weeks; 14 patients (66.67%) had 
more than 1 PU. Most PUs (16; 76.19%) started to granulate, 
4 (19.05%) wounds were covered with slough, and in 1 PU 
(4.76%) reepithelialization occurred. Between ES treatments, 
hydrogel dressings were applied in 11 (52.38%) patients, hy-
drocolloid dressings in 7 (33.33%) patients, and alginate in 3 
(14.29%) patients. The mean PSBF was 37.37 ± 21.50 perfu-
sion units, and blood flow in healthy skin approximately 20 
cm to 30 cm from the edges of the wound was 12.07 ± 7.52 
perfusion units.    
Placebo ES group characteristics. The PG included 20 pa-
tients (8 women and 12 men, average age 52.50 ± 13.18 years). 
Mean PU risk as per the Norton and Waterlow Scales was 
10.05 ± 1.96 and 31.8 ± 8.13, respectively. Two (2, 10%) pa-
tients were obese (BMI >30) and 5 (25%) were underweight 
(BMI <18.5); 13 (65%) were immobile and needed assistance 
to change position, 9 (45%) smoked cigarettes, and 14 (70%) 
were malnourished and were administered nutrition therapy. 
Ten (10) patients (50%) had spinal cord injury, 9 (45%) had 
experienced a cerebral stroke, and 1 (5%) had a head injury. 
Nine (9; 45%) patients had tetra- or quadriplegia, 5 (25%) 
had paraplegia, and 6 (30%) had hemiparesis. Six (6) patients 
(30%) had type 2 diabetes and 6 (30%) had anemia.   
The mean size of the 20 PUs was 25.12 ± 17.42 cm2; 3 were 
Stage 2 (15%), 13 Stage 3 (65%), and 4 Stage 4 (20%). Most 
were located in the sacral region (14; 70%), 3 (15%) on the 
ischial tuberosity or the trochanter, and 3 (15%) were on the 
lower extremities (lower leg and foot). The mean duration 
of the PUs was 10.85 ± 8.59 weeks; 14 patients (70%) had 
more than 1 PU. At baseline, more than half of the PUs in the 
study (12; 60%) started to granulate, 6 (30%) were covered 
with slough, and in 2 PUs (10%) reepithelialization occurred. 
Between ES treatments, 14 patients (70%) received hydrogel 
dressings, 5 (25%) received hydrocolloid dressings, and 1 
(5%) received alginate. Mean PSBF was 45.61 ± 15.73 perfu-
sion units, and blood flow in healthy skin approximately 20 
cm to 30 cm from the edges of the wound was 13.76 ± 4.54 
perfusion units.    
Primary outcome. The cumulative change in PSBF flow 
after 2 weeks of treatment (PSBF2) was 109.52% (95% confi-
dence interval [CI]: 44.59-174.45) for the AG, 131.54% (95% 
CI: 60.28-202.80) for the CG, and 35.83% (95% CI: 14.63-
57.02) for the PG (see Table 4). The CIs of the mean PSBF2 
values overlapped between AG:PG and CG:PG, but the mean 
PSBF2 calculated for the PG was smaller than the smallest 
CIs for the AG and the CG, showing that the results obtained 
for AG and CG groups were statistically more significant than 
those obtained for the PG. These results were supported by 
the ANOVA Kruskal-Wallis and post-hoc Kruskal-Wallis 
tests. The ANOVA Kruskal-Wallis test showed changes in 
PBSF were significantly different among the 3 groups (AG, 
CG, PG; P = .0129). The post-hoc Kruskal-Wallis test showed 
statistically significant differences between the AG and PG 
Table 3. Baseline patient and pressure ulcer characteristics (N=61)
Variable Anode ES group Cathode ES group Placebo ES group 
aLocation (n, %)
  Sacrum 15 (75%) 16 (76.19%) 14 (70%)
  Ischial tuberosity or trochanter major 2 (10%) 2 (9.52%) 3 (15%)
  Lower leg or foot 3 (15%) 3 (14.29%) 3 (15%)
aPU characteristic/stage of healing (n, %)
  Slough present 6 (30%) 4 (19.05%) 6 (30%)
  Granulating 13 (65%) 16 (76.20%) 12 (60%)
  Reepithelializing 1 (5%) 1 (4.76%) 2 (10%)
achi-squared 
bANOVA Kruskall-Wallis Test
cpost-hoc Kruskal-Wallis Test 
In all tests, the between-group differences were not statistically significant (P >.05) 
SD=standard deviation; ES=electrical stimulation; WSA=wound surface area; PU=pressure ulcer;NPUAP=National Pressure Ulcer Advisory Panel
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groups (P = .0470) and CG and PG groups (P = .0152). The 
AG and CG were not found to be significantly different from 
each other (P = .9999) (see Table 4).
The cumulative change in PSBF after 4 weeks of treat-
ment (PSBF4) was 89.30% (95% CI: 21.79-156.81) for the 
AG, 88.25% (95% CI: 18.19-158.30) for the CG, and 34.53% 
(95% CI: 13.90-55.16) for the PG. Differences among AG, 
CG, and PG were not statistically significant: the ANOVA 
Kruskal-Wallis test showed P = .74, and the post-hoc Krus-
kal-Wallis tests showed that in AG versus CG P = .9999; in 
AG versus PG P = .9999; and in CG versus PG P = .9999 (see 
Table 4). 
Secondary outcomes. The nonlinear approximation of 
treatment results showed that to decrease WSA from baseline 
by half (T½) would require 4.30 weeks of treatment (95% 
CI: 0.20-0.26) in the AG, 3.86 (95% CI: 0.23-0.28) in the CG, 
and 9.86 (95% CI: 0.09-0.12) in the PG. The analysis of CIs 
for T½ showed that the periods were statistically significant 
different between the AG and the PG and between the CG 
and the PG (P <.05) but not between the AG and the CG (see 
Table 5 and Figure 2).
The cumulative percentage area reduction after 8 weeks 
of treatment (PAR8) was 64.10% (95% CI: 50.42-77.78) 
for the AG, 74.06% (95% CI: 63.48-84.63) for the CG, and 
41.42% (95% CI: 28.37-54.47) for the PG. The PAR8 for 
CG was significantly higher statistically than that obtained 
Table 4. Periwound skin blood flow (N=61)
Group Periwound skin blood flow Percentage change in periwound skin 
blood flow
[Perfusion unit] At week 2 At week 4 [%] Between baseline 
and week 4
Anode ES group/AG 
N=20
46.42 (20.42)
27.59–47.16
79.82 (27.37)
67.01–92.63
64.66 (23.83)
53.51–75.81
109.52 (138.73)
44.59 – 174.45
89.30 (144.25)
21.79–156.81
Cathode ES group/
CG N=21
37.37 (21.50)
27.58–47.16
68.30 (30.75)
54.31–82.30
51.33 (27.83)
38.66–63.95
131.54 (156.55)
60.28 – 202.80
88.25 (153.90)
18.19–158.30
Placebo group/PG 
N=20
45.61 (15.73)
38.24–52.97
59.77 (25.58)
47.80–71.75
56.54 (16.62)
48.76–64.32
35.83 (45.29)
14.63 – 57.02
34.53 (44.08)
13.90–55.16
Level of significance aP(AG:CG:PG)=.0129; 
bP(AG vs CG)=.9999; 
bP(AG vs PG)=.0470; 
bP(CG vs PG)=.0152;
aP(AG:CG:PG)=74
bP(AG vs CG)=.9999; 
bP(AG vs PG)=.9999; 
bP(CG vs PG)=.9999
aANOVA Kruskal-Wallis Test. bpost-hoc Kruskal-Wallis Test; ES=electrical stimulation
Table 5.  Nonlinear exponential approximation of time necessary for wound area to decrease by half from 
baseline (N=61)
Group T1/2 Confidence interval Significance level of the differences T1/2 between groups
-95% +95%
Anode ES group AG 4.30 0.202 0.262 P(AG vs CG)>.05
Cathode ES group CG 3.86 0.233 0.284 P(AG vs PG)≤.05
Placebo group PG 9.86 0.087 0.116 P(CG vs PG)≤.05
Figure 2. Nonlinear exponential approximation of the 
length of time necessary for wound area to decrease by 
half from baseline (dots correspond to observed mean 
values of relative wound surface area; whiskers repre-
sent 95% confidence interval). The length of treatment 
necessary for wound surface area to decrease from 
baseline by half (T1/2) was 4.30 weeks in the anodal 
group (AG), 3.86 weeks in the cathodal ES group (CG), 
and 9.86 weeks in the sham group (PG). The analysis of 
confidence intervals for T1/2 showed that the lengths 
were significantly different between the AG and PG (P 
<.05) and between the CG and PG (P <.05). 
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for the PG, as indicated by nonoverlapping CIs of the mean 
PAR8 values and results of the post-hoc Kruskal-Wallis test 
(P = .0024). The CIs for the mean PAR8 values overlapped 
between AG:PG, but the mean PAR8 for PG was smaller than 
the smallest confidence intervals for AG, meaning that results 
obtained for the AG were also statistically more significant 
than those obtained for the PG. The finding was supported 
by the post-hoc Kruskal-Wallis test (P = .0391). No statisti-
cally significant differences were noted between the AG and 
the CG (P = .9999) (see Table 6).
Over 8 weeks of treatment, 4 
of the 20 (20%) PUs in the AG, 7 
of 21 (33%) in the CG, and 2 of 
20 (10%) in the PG closed. Dif-
ferences among the groups were 
not statistically significant: for 
AG versus PG, P = .3721; for CG 
versus PG, P = .0645; and for AG 
versus CG, P =.3331. Average du-
ration of treatment to wound clo-
sure was 6.7 weeks (95% CI: 5.04-
8.36) in the AG, 7.38 weeks (95% 
CI: 5.72-9.04) in the CG, and 6.05 
weeks (95% CI: 4.92-7.18) in the 
PG. Differences among the groups 
(AG:CG:PG) were not statistically 
significant (P = .5111).
In the AG, PSBF at baseline 
(PSBF0) was negatively correlated 
with percentage wound area reduction after 2 weeks of treat-
ment (PAR 0-2; P = .0361), meaning that greater baseline 
PSBF was associated with smaller reduction in wound area 
over the first 2 weeks of therapy. A positive correlation be-
tween PSBF at week 2 (PSBF2) and week 4 (PSBF4) and per-
centage wound area reduction between weeks 2 and 4 (PAR 
2-4), as well as between weeks 4–8 (PAR 4-8), was indicative 
of a positive relationship between greater PSBF and a smaller 
reduction in wound area. In the AG, positive correlation be-
tween PSBF4 and PAR 4 to 8 was statistically significant (P = 
.049; see Table 7). In the CG, positive correlation (although 
not statistically significant [P = .161]) was established be-
tween PSBF at week 4 and PAR 4–8. For PG, no positive cor-
relations between blood flow at weeks 2 and 4 and PAR 2–4 
and PAR 4–8 were determined (see Table 7). 
No adverse effects of applying HVMPC were observed in 
this study. 
Discussion
Statement and principal findings. The trial has shown 
that in patients with neurological injuries an 8-week treat-
ment program consisting of SWC plus anodal HVMPC 
and/or SWC plus cathodal HVMPC can increase PSBF 
and reduce PU surface area more significantly than SWC 
alone. PUs treated with SWC plus anodal and cathodal ES 
decreased in size by half, significantly faster than when only 
SWC was provided. 
In this trial, increases in PSBF measured at weeks 2 and 
4 of treatment were not significantly different between 
groups receiving anodal and cathodal ES, nor was percent-
age wound area reduction significantly different between 
groups after 8 weeks of treatment. This implies anodal and 
cathodal HVMPC have a similar effect on PSBF and PU area 
reduction. In both groups receiving HVMPC, the amount of 
blood flow in wound edges and WSA decrease were positively 
Table 6. Pressure ulcer size (n=61)
Mean (SD)
95% Confidence interval
Group Wound surface area 
(cm2)
Percentage area 
reduction (%)
Before treatment At week 8 At week 8
Anode ES group/AG 
N=20
17.88 (18.68)
9.13–26.62
8.32 (11.76)
2.82–13.82
64.10 (29.22)
50.42– 77.78
Cathode ES group/
CG N=21
19.25 (16.47)
11.76–26.75
6.46 (8.97)
2.37–10.54
74.06 (23.23)
63.48–84.63
Placebo group/PG 
N=20
25.12 (17.42)
16.96–33.27
16.38 (13.90)
9.88–22.89
41.42 (27.88)
28.37 – 54.47
Level of significance aP(AG:CG:PG)=.0026;
bP(AG vs. CG)=.9999;
bP(AG vs. PG)=.0391;
bP(CG vs. PG)=.0024
aANOVA Kruskal-Wallis Test; bpost-hoc Kruskal-Wallis Test
Table 7. Correlationsa between periwound skin 
blood flow (PSBF) and percent wound area 
reduction (PAR) (N=61)
Variables N R P
Anode ES group
PSBF at week 0: PAR 2 (%) 20 -0.433 .036
PSBF at week 2: PAR2–4 (%) 20 0.122 .608
PSBF at week 4: PAR 4–8 (%) 20 0.389 .049
Cathode ES group
PSBF at week 0: PAR 2 (%) 21 0.103 .656
PSBF at week 2: PAR 2-4 (%) 21 -0.064 .784
PSBF at week 4: PAR 4–8 (%) 21 0.318 .161
Placebo ES group (control)
PSBF at week 0: PAR 2 (%) 20 0.064 .788
PSBF at week 2: PAR 2–4 (%) 20 -0.139 .557
PSBF at week 4: PAR 4–8 (%) 20 -0.120 .612
aSpearman’s rank correlation; N=number; R=correlation coefficient; P 
=level of significance
PAR 2 percentage wound area reduction at week 2 in relation to base-
line; PAR 2–4 percentage wound area reduction at week 4 in relation to 
week 2;PAR 4–8 percentage wound area reduction at week 8 in relation 
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correlated with each other. In the group treated with anodal HVMPC, a positive 
correlation between the amount of blood flow after 2 weeks of treatment and WSA 
decrease between weeks 2 and 4 was observed. In both ES groups, the amount of 
blood flow at week 4 of treatment positively correlated with WSA decrease between 
weeks 4 and 8. In the anodal ES group, the correlation was statistically significant. 
In the control group, positive correlations between the amount of blood flow af-
ter weeks 2 and 4 of treatment and WSA decrease between weeks 2 and 4 and 4 
and 8 were not noted. More research is necessary to determine the exact role of 
wound blood flow changes observed with HVMPC and between anodal and cath-
odal HVMPC in PU wound healing. 
The primary research outcome in this study was percentage change in PSBF after 
2 and 4 weeks of treatment. After 2 weeks of applying HVMPC, PSBF increased in 
the AG by 109.52% and in the CG by 131.54%. Both rates were significantly higher 
than in the PG (35.83%). Between weeks 2 and 4 of treatment, PSBF slightly de-
creased in all groups studied, but after 4 weeks it was still higher than at baseline by 
89.3% in the AG, 88.25% in the CG, and 34.53% in the PG. No clinical studies were 
found that compared how anodal and cathodal HVMPC influences PSBF and area 
reduction of PUs (or other chronic wounds).
Several clinical studies22-24 on wounds of mixed etiology (including PUs and 
diabetic foot ulcers) showed biphasic currents increase PSBF and reduce wound 
area, results similar to those obtained in the present study. In these studies,22-24 
researchers applied biphasic charge-balanced sine wave current (30 Hz; 250 µs; 20 
mA) for 30 minutes once a day, 3 times a week, for 4 weeks. Current was delivered 
via electrodes attached to the opposite wound edges. In these 3 studies,22-24 as well 
as in the present study, current amplitude was set at sensory level without eliciting 
muscle contractions. 
In the randomized clinical study by Lawson and Petrofsky,22 ES was applied to 2 
groups of 10 patients with Stage 3 and Stage 4 chronic wounds of mixed etiology. 
The groups included patients with type 2 diabetes (mean age 64.7 years; mean ulcer 
duration 10.6 months) and nondiabetic patients (mean age 55.3 years; mean ulcer 
duration 12.7 months). Both groups received ES. After 2 weeks of treatment, PSBF 
measured before an ES procedure in patients with diabetes was 35% greater than at 
baseline and significantly greater than in nondiabetic patients whose PSBF did not 
change over that period (P <.003). At week 4 of treatment, PSBF before ES in pa-
tients with diabetes was 21% greater than at baseline and in nondiabetic patients an 
increase of 18% was noted (P >.05). PSBF in patients with diabetes measured during 
ES was significantly greater than in nondiabetic patients after both 2 and 4 weeks of 
treatment. At week 2, the PSBF in patients with diabetes increased by 215%, as op-
posed to nondiabetic patients’ whose PSBF did not change significantly (P <.003). 
PBSF measured at week 4 in patients with diabetes was 87% higher compared with 
only 6% in nondiabetic patients (P <.003). Lawson and Petrofsky22 also noted that 
the 4-week healing rate for patients with diabetes was 70.0%, while the healing rate 
for the other patients was 38.4%, a statistically significant difference (P <.01).   
Suh et al23 conducted a pilot study without a control group where 18 persons (10 
men, 8 women, mean age 35.7 years) with chronic ulcers of mixed etiology (mainly 
Stage 3 and Stage 4 PUs and diabetic ulcers; mean area 10.7 cm2) unhealed after 26.1 
months’ duration received ES. Twenty (20) minutes before each ES procedure, the 
wound and periwound skin were warmed to 37˚ C using thermal energy from an IR 
heat lamp. This temperature was maintained until the ES procedure ended. After 4 
weeks of treatment, a mean increase in PSBF recorded 20 minutes after the lamp 
was switched on was 9.3% (P >.05); the application of ES resulted in a significant 
increase in PSBF by an average of 15.6% (P <.05) after 30 minutes. During the 
4 weeks of treatment, wound measurements decreased by 43.4% (P <.05). The 
authors also observed that PSBF increased from the beginning and well past the 
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middle of the study (2 weeks) (P <.05) but decreased to-
ward the end of treatment (statistically, the changes were 
not significant;P >.05).     
In a longitudinal, randomized, clinical study by Petrof-
sky et al,24 20 patients (mean age 48.4 years) with nonheal-
ing diabetic foot ulcers (mean duration 38.9 months) were 
randomly divided into 2 groups. Groups were treated with 
local dry heat (heat group; n = 10; mean WSA was 28.2 cm2) 
or local dry heat + ES (heat + ES group; n = 10; mean WSA 
was 24.1 cm2). In both groups, local heating was provided 
by an IR lamp positioned 5 cm above the wound to warm 
the wound area to 37˚ C. Before treatment, the average blood 
flow was greatest in the center of the wounds. The average 
blood flow for all participants in both groups was 112.3 flux 
in the outside of the wound, 224.3 flux on the edge of the 
wound, and 385.7 flux in the center of the wound. On the 
first day of the study, the average blood flow from all 3 areas 
increased from baseline by 102.3% in the heat group and by 
152.3% in the heat + ES group. By the last day of the study, 
the average blood flow in all 3 areas had decreased by 54.5% 
in both groups. Blood flow differences between the groups 
were not significant, but percentage wound area reduction in 
the heat + ES group at week 4 was significantly greater than 
in the heat group (68.4% and 30.1%, respectively; P <.05). 
The authors of the cited studies22-24 reported blood flow 
was greater after weeks 2 and 4 of treatment than at base-
line. As in the current study, blood flow was at its highest 
at week 2 and then decreased. The authors also stated that 
after 4 weeks of treatment with biphasic current surface 
area of mixed etiology, wound size decreased from 38.4% to 
70%. In the current study, 8 weeks of treatment with anodal 
and cathodal HVMPC reduced wound area by 64.10% and 
74.06%, respectively.            
In the cited studies,22-24 blood flow was measured using 
laser Doppler imaging and computerized image analysis. A 
study on healthy people by Wikstrom et al40 found both la-
ser Doppler flowmetry and intravital video microscopy to be 
useful in studying the microcirculation in the healthy skin 
and in the skin around experimental blister wounds. In the 
present study, Doppler flowmetry was used; skin temperature 
under the probe head was 33˚ C. In the cited studies,22-24 skin 
temperature during ES procedures and PSBF measurements 
was 37˚ C. In the study by Petrofsky et al38 among healthy 
men, biphasic square wave ES (30 Hz; 250 µs; 15 minutes; 15 
mA) increased skin blood flow when skin temperature was 
maintained at 30˚ C and 40˚ C, but at 20˚ C no significant 
change in skin blood flow was observed. 
The secondary research outcome in the current study was 
the healing rate and percentage decrease in PU surface area, 
which also was used by the authors of other clinical studies 
evaluating the efficacy of wound treatment.10-18 The percent-
age reduction in wound area noted at week 8 was significant-
ly greater in the AG and CG than in the PG (64.10% in the 
AG, 74.06% in the CG, and 41.42% in the PG). The authors 
found the approximate length of treatment necessary to de-
crease area in Stage 2 to Stage 4 PUs by 50% was 4.30 weeks in 
the AG and 3.86 weeks in the CG —  in both scenarios, times 
significantly shorter statistically than in the PG (9.86 weeks). 
Thus far, no clinical studies have compared the influence 
of anodal and cathodal HVMPC or other electrical currents 
on the healing of PUs or other types of wounds. However, the 
results of the existing clinical research show both anodal and 
cathodal HVMPC promote the healing of PUs, which sup-
ports present results.10,11,17,18  
In the study by Kloth and Feedar,10 anodal stimulation 
with HVMPC + SWC (9 patients) decreased the surface area 
of Stage 4 PUs by an average of 44.8% a week. Wounds closed 
completely over a period of 7.3 weeks. In the control group 
(7 patients) that received sham ES + SWC, wound area in-
creased by 28.8% over a mean period of 7.4 weeks. 
In Griffin et al,11 HVMPC + SWC decreased the area of 8 
Stage 2 to Stage 4 PUs by 80% after 3 weeks of cathodal ES, a 
result that was significantly greater than in the control group 
(sham ES + SWC; 9 patients), where PUs decreased by an av-
erage of 52% (P <.05). 
In the study by Polak et al,17 6 weeks of cathodal HVMPC 
+ SWC (25 patients) decreased the area of Stage 2 to Stage 3 
PUs by 88.31%, also significantly better than in the control 
group (sham HVMPC + SWC; 24 patients) where wound 
area decreased by an average of 54.65% (P = .046). The Po-
lak et al17 study also showed that in the group treated with 
cathodal HVMPC + SWC, 45% of Stage 2 PUs and 17.65% 
of Stage 3 PUs closed after 6 weeks of treatment compared 
with 35.29% of Stage 2 PUs and 6.25% of Stage 3 PUs in the 
control group (sham HVMPC + SWC). The results were not 
significantly different between the groups (P = .74 and P = 
.60, respectively). 
In an additional study by Polak et al,18 the surface area of 
23 Stage 2 to Stage 4 PUs decreased after 6 weeks of cathodal 
HVMPC + SWC by an average of 82.34%. This result was sig-
nificantly greater than in the control group (sham HVMPC 
+ SWC), where average decrease in WSA was 40.53% (P = 
.0006). Cathodal HVMPC was therapeutically as effective as 
1 week of anodal stimulation followed by 5 weeks of cath-
odal stimulation that reduced WSA by 70.77% (P = .9932). 
WSA decrease induced by anodal plus cathodal stimulation 
also was significantly greater than in the control group (P = 
.0124). In the group treated with cathodal HVMPC + SWC, 
47.8% of Stage 2 to Stage 4 PUs closed over 6 weeks, com-
pared with 45% of Stage 2 to Stage 4 PUs (P = .48) in the 
group receiving anodal plus cathodal HVMPC + SWC. In 
both ES groups, the percentage of PUs that closed was signifi-
cantly greater than in the control group, where not a single 
PU closed (P = .013 and P = .045, respectively).    
Implications for clinicians and policymakers. In design-
ing the protocol for the application of HVMPC, the authors 
referred to solutions used by other authors.10-18 After steril-
izing, the treatment electrode was placed on the wound and 
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the return electrode on intact periwound skin at least 15 cm 
from the wound edge. Both electrodes were separated from 
the tissue by sterile gauze pads, which were moistened with 
physiological saline to improve electrical conductivity and 
maintain a moist wound environment.
Previous and present research showed HVMPC with twin-
peaked pulses (50-154 µs, 100 pps) used to treat PUs,10,11,15-18 
venous leg ulcers,12,14 and diabetic foot ulcers13 is therapeuti-
cally efficient. In the study, 0.36 A and an electric charge of 
360 µC/sec (1.08 C/day) in the voltage range from 100 to 150 
V was applied; in other studies, the electrical charge ranged 
from 250 – 500 µC/sec (0.89 – 1.78 C/day).10,11,17-20,41 Follow-
ing the protocols used by other researchers,10-18 the amperage 
used in the present study could be detected only by cutane-
ous receptors.
Most authors10-12,14,16-18 applied HVMPC to wounds for 45 
minutes to 60 minutes, once a day, 3 to 7 days a week, so 
treatment time ranged from 2.25 to 7 hours per week. The 
sessions in this study were similar in duration (50 minutes, 
5 days/week; total treatment time of 4.16 hours of a week). 
The results of preclinical ES reports7,42-44 note the polarity 
of the treatment electrode is important in managing chronic 
wounds, but this clinical trial appears to be the first to com-
pare PUs treated with anodal versus cathodal HVMPC. More 
clinical research is necessary to determine how the polarity 
of the treatment electrode influences wound healing. More 
research is also necessary to determine whether anodal or 
cathodal HVMPC accelerates wound healing by stimulat-
ing blood flow in the wound area. Future clinical trials also 
should investigate the influence of electrical currents on the 
concentrations of pro- and anti-inflammatory factors such as 
cytokines and growth factors in wounds.     
Limitations
This study has several strengths. First, the research team 
(physicians, nurses, physiotherapists), the person in charge 
of measuring WSA, and the statistician were blinded as to 
treatment provided. Second, the participants were hospital-
ized at the same rehabilitation center, making it possible for 
the medical staff to supervise the uniform application of 
PU prevention measures and treatments and to ensure the 
ES protocol was observed at all times. Third, wound sizes 
were measured based on valid and reliable acetate tracings. 
Fourth, all patients completed at least 4 weeks of treatment, 
so PSBF4 and PAR4 could be calculated and compared for 
all of them. Finally, the intent-to-treat analysis employed 
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the exponential regression function, which allows WSA de-
creases to be precisely represented, to approximate the likely 
treatment results between weeks 4 and 8.
However, the study was not without limitations. A ma-
jor limitation of the study is that the period of treatment 
was insufficient for all PUs to close. Consequently, length of 
treatment (ie, optimal treatment time of anodal or cathodal 
HVMPC to facilitate complete closure of Stage 2 to Stage 
4 PUs) could not be determined. The blinding rate of pa-
tients and assessors was not assessed. Another limitation 
is the relatively high dropout rate between weeks 4 and 8 
(31.15%); some patients were discharged from the hospital 
to be treated at home and a number of others were moved 
to other wards for treatment for concomitant diseases. This 
thwarted the monitoring of the healing of their PUs. The PU 
prevention and treatment program for all 3 groups gener-
ally followed the same best practice recommendations,1,2,37 
but its specific solutions addressed the needs of individual 
patients. Finally, the sample size in each group was too small 
to control for the potential effect of baseline variables such 
as ulcer depth/stage and start of treatment wound charac-
teristics on study outcomes.
Conclusion
This study demonstrated that anodal and cathodal 
HVMPC with double-peaked impulses (154 µs; 100 pps; 
above 100 V; 360 µC/sec; 1.08 C/day) administered 50 min-
utes a day, 5 times a week, can be used in clinical practice to 
improve PSBF and promote healing of Stage 2 to Stage 4 PUs 
in patients with neurological injuries. These results are con-
sistent with those obtained by other researchers who also re-
ported HVMPC can improve the healing of chronic wounds, 
including PUs. However, this is the first study to document 
that type of ES (anodal or cathodal) did not affect wound 
blood flow and wound size reduction in patients with PUs. 
Future clinical trials are necessary to elucidate the nature 
of the relationship between the stimulation of wound blood 
flow following anodal and cathodal HVMPC and change in 
wound area. n
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